

Table 1 Clinical Characteristics

Variables	DM Group (n, 60)	Non-DM Group (n, 89)	<i>P</i> value
Age, years	68.8±6.5	68.4±5.6	0.274
BMI, kg/m ²	24.9±1.8	24.5±2.1	0.131
Gender, sex			0.688
Women, n (%)	31 (52%)	43 (48%)	-
Men, n (%)	29 (48%)	46 (52%)	-
Concomitant diseases			
Hypertension, n (%)	43 (72%)	47 (53%)	0.021
Dyslipidemia, n (%)	26 (43%)	26 (29%)	0.076
Smoking, n (%)	41 (58%)	56 (63%)	0.497
Coronary heart disease, n (%)	35 (58%)	48 (54%)	0.596
Renal Failure, n (%)	9 (15%)	18 (20%)	0.417
Stroke, n (%)	12 (20%)	19 (21%)	0.842
COPD, n (%)	13 (22%)	16 (18%)	0.577
Peripheral ischemia, n (%)	9 (15%)	13 (15%)	0.947
Medical treatment of IMHB			
ACEI/ARB, n (%)	20 (33%)	22 (24%)	0.252
β-blockers, n (%)	55 (92%)	82 (92%)	1.000
Calcium antagonists, n (%)	18 (30%)	21 (24%)	0.383
Urapidil, n (%)	55 (92%)	79 (89%)	0.564
Sodium nitroprusside, n (%)	15 (25%)	25 (28%)	0.676
Laboratory test on Admission			
White blood cell (10 ⁹ /L)	14.2±1.9	18.3±3.7	<0.001
C-reactive protein (mg/dL)	5.7±1.5	11.3±2.9	<0.001
Hemoglobin A1c (%)	7.9±0.8	4.8±0.8	<0.001
Fasting Plasms Glucose (mg/dL)	169.8±15.6	93.6±9.1	<0.001
2-hours Plasma Glucose (mg/dL)	286.2±41.2	130.3±5.6	<0.001
Geometric Measurements			
Diameter of ascending aorta (mm)	37.9±2.5	39.9±3.8	0.003
Diameter of descending aorta (mm)	34.9±2.8	37.9±3.5	<0.001

Hematoma thickness (mm)	7.0±1.3	9.5±1.2	<0.001
--------------------------------	---------	---------	--------

*Some patients had focal intimal disruption in different zones.

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IMHB, type B intramural hematoma; ULP, ulcer-like projection;